These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 10942043)
1. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Kem WR Behav Brain Res; 2000 Aug; 113(1-2):169-81. PubMed ID: 10942043 [TBL] [Abstract][Full Text] [Related]
2. Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration. Kem WR; Mahnir VM; Prokai L; Papke RL; Cao X; LeFrancois S; Wildeboer K; Prokai-Tatrai K; Porter-Papke J; Soti F Mol Pharmacol; 2004 Jan; 65(1):56-67. PubMed ID: 14722237 [TBL] [Abstract][Full Text] [Related]
3. Alpha7 nicotinic acetylcholine receptor-specific agonist DMXBA (GTS-21) attenuates Aβ accumulation through suppression of neuronal γ-secretase activity and promotion of microglial amyloid-β phagocytosis and ameliorates cognitive impairment in a mouse model of Alzheimer's disease. Takata K; Amamiya T; Mizoguchi H; Kawanishi S; Kuroda E; Kitamura R; Ito A; Saito Y; Tawa M; Nagasawa T; Okamoto H; Sugino Y; Takegami S; Kitade T; Toda Y; Kem WR; Kitamura Y; Shimohama S; Ashihara E Neurobiol Aging; 2018 Feb; 62():197-209. PubMed ID: 29175709 [TBL] [Abstract][Full Text] [Related]